Suppression of pain-related behavior in two distinct rodent models of peripheral neuropathy by a homopolyarginine-conjugated CRMP2 peptide

Weina Ju, Qi Li, Yohance M. Allette, Matthew S. Ripsch, Fletcher A. White, Rajesh Khanna

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The N-type voltage-gated calcium channel (CaV2.2) is a clinically endorsed target in chronic pain treatments. As directly targeting the channel can lead to multiple adverse side effects, targeting modulators of CaV2.2 may prove better. We previously identified ST1-104, a short peptide from the collapsin response mediator protein 2 (CRMP2), which disrupted the CaV2.2-CRMP2 interaction and suppressed a model of HIV-related neuropathy induced by anti-retroviral therapy but not traumatic neuropathy. Here, we report ST2-104 -a peptide wherein the cell-penetrating TAT motif has been supplanted with a homopolyarginine motif, which dose-dependently inhibits the CaV2.2-CRMP2 interaction and inhibits depolarization-evoked Ca2+ influx in sensory neurons. Ca2+ influx via activation of vanilloid receptors is not affected by either peptide. Systemic administration of ST2-104 does not affect thermal or tactile nociceptive behavioral changes. Importantly, ST2-104 transiently reduces persistent mechanical hypersensitivity induced by systemic administration of the anti-retroviral drug 2′,3′-dideoxycytidine (ddC) and following tibial nerve injury (TNI). Possible mechanistic explanations for the broader efficacy of ST2-104 are discussed. Chronic neuropathic pain remains a worldwide medical problem with few effective therapies. Drugs targeting calcium channels are in clinical use as first-line treatments for alleviation of neuropathic pain. However, targeting these channels can lead to serious complications. Here, we report that a peptide derived from CRMP2 - a modulator of calcium channels, offers problem-free pain relief in rodent models of neuropathic pain.

Original languageEnglish (US)
Pages (from-to)869-879
Number of pages11
JournalJournal of Neurochemistry
Volume124
Issue number6
DOIs
StatePublished - Mar 2013
Externally publishedYes

Fingerprint

Peripheral Nervous System Diseases
Rodentia
Neuralgia
Calcium Channels
Pain
Peptides
Chronic Pain
Modulators
Zalcitabine
Cell-Penetrating Peptides
TRPV Cation Channels
Tibial Nerve
Depolarization
Touch
Sensory Receptor Cells
Therapeutics
Drug Delivery Systems
Medical problems
Neurons
Hypersensitivity

Keywords

  • calcium imaging
  • CaV2.2
  • CRMP2
  • neuropathic pain
  • peptide inhibitor
  • polyarginine motif

ASJC Scopus subject areas

  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

Suppression of pain-related behavior in two distinct rodent models of peripheral neuropathy by a homopolyarginine-conjugated CRMP2 peptide. / Ju, Weina; Li, Qi; Allette, Yohance M.; Ripsch, Matthew S.; White, Fletcher A.; Khanna, Rajesh.

In: Journal of Neurochemistry, Vol. 124, No. 6, 03.2013, p. 869-879.

Research output: Contribution to journalArticle

Ju, Weina ; Li, Qi ; Allette, Yohance M. ; Ripsch, Matthew S. ; White, Fletcher A. ; Khanna, Rajesh. / Suppression of pain-related behavior in two distinct rodent models of peripheral neuropathy by a homopolyarginine-conjugated CRMP2 peptide. In: Journal of Neurochemistry. 2013 ; Vol. 124, No. 6. pp. 869-879.
@article{0cf3b256bdfd425d83e4c254732a2d95,
title = "Suppression of pain-related behavior in two distinct rodent models of peripheral neuropathy by a homopolyarginine-conjugated CRMP2 peptide",
abstract = "The N-type voltage-gated calcium channel (CaV2.2) is a clinically endorsed target in chronic pain treatments. As directly targeting the channel can lead to multiple adverse side effects, targeting modulators of CaV2.2 may prove better. We previously identified ST1-104, a short peptide from the collapsin response mediator protein 2 (CRMP2), which disrupted the CaV2.2-CRMP2 interaction and suppressed a model of HIV-related neuropathy induced by anti-retroviral therapy but not traumatic neuropathy. Here, we report ST2-104 -a peptide wherein the cell-penetrating TAT motif has been supplanted with a homopolyarginine motif, which dose-dependently inhibits the CaV2.2-CRMP2 interaction and inhibits depolarization-evoked Ca2+ influx in sensory neurons. Ca2+ influx via activation of vanilloid receptors is not affected by either peptide. Systemic administration of ST2-104 does not affect thermal or tactile nociceptive behavioral changes. Importantly, ST2-104 transiently reduces persistent mechanical hypersensitivity induced by systemic administration of the anti-retroviral drug 2′,3′-dideoxycytidine (ddC) and following tibial nerve injury (TNI). Possible mechanistic explanations for the broader efficacy of ST2-104 are discussed. Chronic neuropathic pain remains a worldwide medical problem with few effective therapies. Drugs targeting calcium channels are in clinical use as first-line treatments for alleviation of neuropathic pain. However, targeting these channels can lead to serious complications. Here, we report that a peptide derived from CRMP2 - a modulator of calcium channels, offers problem-free pain relief in rodent models of neuropathic pain.",
keywords = "calcium imaging, CaV2.2, CRMP2, neuropathic pain, peptide inhibitor, polyarginine motif",
author = "Weina Ju and Qi Li and Allette, {Yohance M.} and Ripsch, {Matthew S.} and White, {Fletcher A.} and Rajesh Khanna",
year = "2013",
month = "3",
doi = "10.1111/jnc.12070",
language = "English (US)",
volume = "124",
pages = "869--879",
journal = "Journal of Neurochemistry",
issn = "0022-3042",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Suppression of pain-related behavior in two distinct rodent models of peripheral neuropathy by a homopolyarginine-conjugated CRMP2 peptide

AU - Ju, Weina

AU - Li, Qi

AU - Allette, Yohance M.

AU - Ripsch, Matthew S.

AU - White, Fletcher A.

AU - Khanna, Rajesh

PY - 2013/3

Y1 - 2013/3

N2 - The N-type voltage-gated calcium channel (CaV2.2) is a clinically endorsed target in chronic pain treatments. As directly targeting the channel can lead to multiple adverse side effects, targeting modulators of CaV2.2 may prove better. We previously identified ST1-104, a short peptide from the collapsin response mediator protein 2 (CRMP2), which disrupted the CaV2.2-CRMP2 interaction and suppressed a model of HIV-related neuropathy induced by anti-retroviral therapy but not traumatic neuropathy. Here, we report ST2-104 -a peptide wherein the cell-penetrating TAT motif has been supplanted with a homopolyarginine motif, which dose-dependently inhibits the CaV2.2-CRMP2 interaction and inhibits depolarization-evoked Ca2+ influx in sensory neurons. Ca2+ influx via activation of vanilloid receptors is not affected by either peptide. Systemic administration of ST2-104 does not affect thermal or tactile nociceptive behavioral changes. Importantly, ST2-104 transiently reduces persistent mechanical hypersensitivity induced by systemic administration of the anti-retroviral drug 2′,3′-dideoxycytidine (ddC) and following tibial nerve injury (TNI). Possible mechanistic explanations for the broader efficacy of ST2-104 are discussed. Chronic neuropathic pain remains a worldwide medical problem with few effective therapies. Drugs targeting calcium channels are in clinical use as first-line treatments for alleviation of neuropathic pain. However, targeting these channels can lead to serious complications. Here, we report that a peptide derived from CRMP2 - a modulator of calcium channels, offers problem-free pain relief in rodent models of neuropathic pain.

AB - The N-type voltage-gated calcium channel (CaV2.2) is a clinically endorsed target in chronic pain treatments. As directly targeting the channel can lead to multiple adverse side effects, targeting modulators of CaV2.2 may prove better. We previously identified ST1-104, a short peptide from the collapsin response mediator protein 2 (CRMP2), which disrupted the CaV2.2-CRMP2 interaction and suppressed a model of HIV-related neuropathy induced by anti-retroviral therapy but not traumatic neuropathy. Here, we report ST2-104 -a peptide wherein the cell-penetrating TAT motif has been supplanted with a homopolyarginine motif, which dose-dependently inhibits the CaV2.2-CRMP2 interaction and inhibits depolarization-evoked Ca2+ influx in sensory neurons. Ca2+ influx via activation of vanilloid receptors is not affected by either peptide. Systemic administration of ST2-104 does not affect thermal or tactile nociceptive behavioral changes. Importantly, ST2-104 transiently reduces persistent mechanical hypersensitivity induced by systemic administration of the anti-retroviral drug 2′,3′-dideoxycytidine (ddC) and following tibial nerve injury (TNI). Possible mechanistic explanations for the broader efficacy of ST2-104 are discussed. Chronic neuropathic pain remains a worldwide medical problem with few effective therapies. Drugs targeting calcium channels are in clinical use as first-line treatments for alleviation of neuropathic pain. However, targeting these channels can lead to serious complications. Here, we report that a peptide derived from CRMP2 - a modulator of calcium channels, offers problem-free pain relief in rodent models of neuropathic pain.

KW - calcium imaging

KW - CaV2.2

KW - CRMP2

KW - neuropathic pain

KW - peptide inhibitor

KW - polyarginine motif

UR - http://www.scopus.com/inward/record.url?scp=84874718658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874718658&partnerID=8YFLogxK

U2 - 10.1111/jnc.12070

DO - 10.1111/jnc.12070

M3 - Article

C2 - 23106100

AN - SCOPUS:84874718658

VL - 124

SP - 869

EP - 879

JO - Journal of Neurochemistry

JF - Journal of Neurochemistry

SN - 0022-3042

IS - 6

ER -